Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07838649). This is a study registration, not published results. Lead sponsor: Washington University School of Medicine. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 36 participants (ESTIMATED). Conditions: Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma. Interventions: DRUG: 68Ga-Galmydar; DEVICE: PET/MRI; DRUG: 18F-FDG. Primary outcome measures: Changes in 68Ga-Galmydar Standardized Uptake Value (SUV) in patients with and without cardiotoxicity , From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks); Correlation between 68Ga-Galmydar PET signal and the 18F-FDG PET signal , From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks); Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from echocardiography , From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks); Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from MR , From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks). Brief summary: This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.